External broker reports(aggregated public sources), HDFC Securities

HDFC Securities

External broker reports(aggregated public sources)

HDFC securities is the best online trading platform for stocks, IPOs, mutual fund in India. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

Equity Bottom-Up

<ul><li>Emami 4QFY24 print was ahead of estimates on the back of a superior product mix and distribution expansion initiatives</li><li>The extended winter drove sales of Boro Plus (up 33% YoY) and pain management (9% YoY), whereas the summer range was partially impacted (up 1% YoY)</li><li>We upgrade Emami to ADD from REDUCE with a TP of INR 600 (27x FY26 EPS, 10% premium to its five-year average PE) as visibility relating to delivering double-digit growth in FY25 has improved significantly on the back of (a) prospects of the strong summer season and a favourable base for the winter season, (b) rural recovery (45-50% of sales) aided via normal monsoon, and (c) distribution expansion initiatives.</li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Emami 4QFY24 print was ahead of estimates on the back of a superior product mix and distribution expansion initiativesThe extended winter drove sales of Boro Plus (up 33% YoY) and pain management (9% YoY), whereas the summer range was partially impacted (up 1% YoY)We upgrade Emami to ADD from REDUCE with a TP of INR 600 (27x FY26 EPS, 10% premium to its five-year average PE) as visibility relating to delivering double-digit growth in FY25 has improved significantly on the back of (a) prospects of the strong summer season and a favourable base for the winter season, (b) rural recovery (45-50% of sales) aided via normal monsoon, and (c) distribution expansion initiatives.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Emami (4QFY24): Sunny Days Ahead. Upgrade to ADD

Thematic (Sector/Industry)

<ul><li>Sun Pharmaceutical Industries: EBITDA grew 10% YoY as sales growth was moderate at 6% YoY (US and global specialty: -2% QoQ, India: +16% YoY) was offset by higher GM (+195 bps) and steady costs (staff/R&amp;D/SG&amp;A was up +2/16/11% YoY)</li><li>SUNP expects growth to improve in subsequent quarters and retains high-single-digit sales growth guidance for FY25</li><li>SUNP sees further headroom for growth in Ilumya and incremental sales from the additional indication (psoriatic arthritis) on approval</li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Sun Pharmaceutical Industries: EBITDA grew 10% YoY as sales growth was moderate at 6% YoY (US and global specialty: -2% QoQ, India: +16% YoY) was offset by higher GM (+195 bps) and steady costs (staff/R&amp;D/SG&amp;A was up +2/16/11% YoY)SUNP expects growth to improve in subsequent quarters and retains high-single-digit sales growth guidance for FY25SUNP sees further headroom for growth in Ilumya and incremental sales from the additional indication (psoriatic arthritis) on approvalContent is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

HSIE Results Daily: Sun Pharmaceutical Industries, Prestige Estates, Phoenix Mills

<ul><li>Britannia Industries: Britannia’s Q1FY24 revenue/EBITDA/PAT growth of 9/38/36% was strong but below expectations</li><li>Transactions grew 9% YoY while volumes were flat, reflecting huge down-trading pressure</li><li>Britannia took price corrections to defend its market share as competitive intensity rose (particularly from local/regional brands)</li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Britannia Industries: Britannia’s Q1FY24 revenue/EBITDA/PAT growth of 9/38/36% was strong but below expectationsTransactions grew 9% YoY while volumes were flat, reflecting huge down-trading pressureBritannia took price corrections to defend its market share as competitive intensity rose (particularly from local/regional brands)Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

HSIE Results Daily: Britannia Industries, Godrej Consumers, Balkrishna Industries

<ul><li>Underlying volume CAGR to sustain revenue to grow by 8/11% on YoY/four-year CAGR: Our FMCG coverage universe is expected to deliver growth of 8/11% on YoY/four-year CAGR in revenue in Q1FY24 (vs 23/10% in Q1FY23 and 9/9% in Q4FY23)</li><li>Continuing from previous quarters the demand environment remained stable led by urban markets while rural recovery was below expectation</li><li>The FMCG sector is expected to witness a gradual recovery in demand led by moderating inflation improving consumer confidence and an increase in government spending</li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Underlying volume CAGR to sustain revenue to grow by 8/11% on YoY/four-year CAGR: Our FMCG coverage universe is expected to deliver growth of 8/11% on YoY/four-year CAGR in revenue in Q1FY24 (vs 23/10% in Q1FY23 and 9/9% in Q4FY23)Continuing from previous quarters the demand environment remained stable led by urban markets while rural recovery was below expectationThe FMCG sector is expected to witness a gradual recovery in demand led by moderating inflation improving consumer confidence and an increase in government spendingContent is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

FMCG & Alco Bev - Slow Pick-Up in Growth, Margin Expansion to Continue

<ul><li>The HSIE consumer index sales grew by 12% YoY in Q4FY23 (+11% in Q4FY22, +11% in Q3FY23)</li><li>On a four-year CAGR basis, the universe clocked 9% growth in Q4FY23, a trend similar to that witnessed in the previous few quarters</li><li>On a four-year CAGR basis, Paints/QSR/F&amp;B/Home Care have grown ahead of our index average (14/13/12/11%) in Q4FY23</li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

The HSIE consumer index sales grew by 12% YoY in Q4FY23 (+11% in Q4FY22, +11% in Q3FY23)On a four-year CAGR basis, the universe clocked 9% growth in Q4FY23, a trend similar to that witnessed in the previous few quartersOn a four-year CAGR basis, Paints/QSR/F&amp;B/Home Care have grown ahead of our index average (14/13/12/11%) in Q4FY23Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

India

Emami Limited develops and distributes personal, beauty, and healthcare products in India and other countries.  The Company manufactures herbal and Ayurvedic products, including antiseptic cream, prickly heat powder, pain balm, and cool oil.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Emami Ltd (HMN IN)

Emami (4QFY24): Sunny Days Ahead. Upgrade to ADD

The extended winter drove sales of Boro Plus (up 33% YoY) and pain management (9% YoY), whereas the summer range was partially impacted (up 1% YoY)

HDFC Securities

HSIE Results Daily: Sun Pharmaceutical Industries, Prestige Estates, Phoenix Mills

Sun Pharmaceutical Industries: EBITDA grew 10% YoY as sales growth was moderate at 6% YoY (US and global specialty: -2% QoQ, India: +16% YoY) was...

HDFC Securities

HSIE Results Daily: Britannia Industries, Godrej Consumers, Balkrishna Industries

Britannia took price corrections to defend its market share as competitive intensity rose (particularly from local/regional brands)

HDFC Securities

FMCG & Alco Bev - Slow Pick-Up in Growth, Margin Expansion to Continue

Continuing from previous quarters the demand environment remained stable led by urban markets while rural recovery was below expectation

HDFC Securities

FMCG: Demand recovery lags margins

On a four-year CAGR basis, the universe clocked 9% growth in Q4FY23, a trend similar to that witnessed in the previous few quarters

HDFC Securities

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)